NCT07559942Recruiting
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
"Effect of Perioperative and Short-Term Apixaban Therapy on Arteriovenous Fistula Maturation in Patients With End-Stage Renal Disease: A Randomized Controlled Trial"
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis \[1\]. AVFs offer superior longevity, fewer infectious complications, and lower mortality rates compared to central venous catheters or synthetic grafts \[2\]. However, a significant limitation to their widespread success is the high rate of early failure, primarily due to failure to mature (FTM). FTM occurs in 20-40% of AVFs, rendering them unusable for dialysis \[3\]. Apixaban, a direct factor Xa inhibitor, offers a potential advantage by providing sustained anticoagulation throughout the critical maturation period \[7\]. Its predictable pharmacokinetics, oral administration, and favorable safety profile make it an attractive agent for short-term use in this setting \[8\]. By reducing microthrombotic events during the first 4-6 weeks following AVF creation, apixaban could potentially improve maturation rates. However, this potential benefit must be weighed against the increased risk of bleeding, hematoma formation, and wound complications that could negatively impact fistula maturation \[9\].
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- First submitted
- 24 Apr 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Combined military hospital lahore
- Diseases
- Chronic kidney disease
- NCT number
- NCT07559942
What you commit to
- Study type: Interventional
- Planned participants: 190
- From 1 Jan 2026 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current dual antiplatelet therapy.
Other illness
- Known bleeding diathesis or hypercoagulable state.
- History of intracranial hemorrhage.
- Known allergy or hypersensitivity to apixaban.
Other
- Current therapeutic anticoagulation (any indication).
- Inability to comply with study protocol or follow-up.
Who the study is looking for
- Age ≥ 18 years.
- Diagnosis of ESRD (eGFR \< 15 mL/min/1.73m² or already on dialysis) with plans for hemodialysis.
- Planned primary upper extremity AVF creation (radiocephalic, brachiocephalic, or brachiobasilic).
- Suitable vessels on preoperative duplex ultrasound (artery ≥ 2 mm, vein ≥ 2.5 mm without tourniquet).
- Ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Combined Military Hospital, Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.